Journal article
ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B
Darren Wong, Margaret Littlejohn, Rosalind Edwards, Kathy Jackson, Peter Revill, Anuj Gaggar, Kathryn Kitrinos, Mani Subramanian, Patrick Marcellin, Maria Buti-Ferret, Harry Janssen, Ed Gane, Stephen Locarnini, Alexander Thompson
LIVER INTERNATIONAL | WILEY | Published : 2018
DOI: 10.1111/liv.13716
Abstract
BACKGROUND: Alanine aminotransferase (ALT) flares during NA therapy are uncommon but occur. Evaluation of ALT flares during nucleos(t)ide analogue (NA) therapy is important as new immunomodulatory therapies for hepatitis B virus (HBV) are developed. We evaluated the association between ALT flares and HBsAg loss during long-term therapy for genotype A CHB. METHODS: This analysis included genotype A subjects from a phase III study of tenofovir vs adefovir in HBeAg-positive HBV. ALT flare was defined as (i) a rise in ALT >2x ULN from normal ALT levels; or (ii) a rise in ALT >2x baseline ALT level. HBsAg response at week 384 was recorded as one of HBsAg loss vs HBsAg decline (≥1 log10 IU/mL dec..
View full abstract